Viva-Thera, XtalPi Nominate HIV Drug Candidate in Seven Months
Boston – September 22, 2026 -- Viva-Thera has nominated a preclinical candidate targeting the membrane-proximal external region (MPER) of HIV-1 gp41, completing discovery and optimization in seven months through a partnership with AI drug-design firm XtalPi (HKEX: 2228). The biotech, incubated and backed by XtalPi as a strategic shareholder, made its public debut disclosing progress across four HIV modalities: vaccines, long-acting small molecules, gene therapy and cell therapy.
XtalPi's AI screened 10 million compounds to isolate five validated hits
Using generative AI, XtalPi navigated a chemical space of approximately 10 million compounds to identify five hits with strong antiviral activity and favorable drug properties. Continuous optimization of these leads drove the program to preclinical candidate nomination within seven months, according to the companies.